2-Methylazonane

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-Methylazonane
• 英文别名: 2-methylazonane
• 化学式: C₉H₁₉N
• 分子量: 141.25
• InChiKey: VVRLVRZTCWCONE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] 3-SULFONYL-5-AMINOPYRIDINE-2,4-DIOL APJ AGONISTS<br/>[FR] AGONISTES D'APJ DE 3-SULFONYL-5-AMINOPYRIDINE -2,4-DIOL
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2018071622A1

  公开（公告）日：2018-04-19

  The present invention provides compounds of Formula (I) wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.

  本发明提供了一种化合物，其化学式为（I），其中所有变量均如规范中定义，并包括任何这种新化合物的组合物。这些化合物是APJ激动剂，可用作药物。
• [EN] OGA INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'OGA
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2019243533A1

  公开（公告）日：2019-12-26

  The present invention relates to O-GIcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations.

  本发明涉及O-GlcNAc水解酶（OGA）抑制剂。该发明还涉及包含这种化合物的药物组合物，制备这种化合物和组合物的方法，以及利用这种化合物和组合物预防和治疗抑制OGA有益的疾病，如tau病变，特别是阿尔茨海默病或进行性上核性麻痹症；以及伴有tau病理的神经退行性疾病，特别是由C90RF72突变引起的肌萎缩侧索硬化或颞叶前叶痴呆症。
• PYRAZOLE DERIVATIVE MANUFACTURING METHOD
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：US20170217958A1

  公开（公告）日：2017-08-03

  The present invention provides a method for manufacturing a compound represented by formula (I). With this method, provided are a method for manufacturing a 4-heteroaryl-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1H-pyrazole-5-carboxylic acid amide derivative; and an intermediate for this manufacturing method. [C217]

  本发明提供了一种制造由化学式(I)表示的化合物的方法。利用这种方法，提供了一种制造4-杂环芳基-N-(2-苯基-[1,2,4]三唑并[1,5-a]吡啶-7-基)-1H-吡唑-5-羧酸酰胺衍生物的方法；以及用于这种制造方法的中间体。
• [EN] METHODS OF MAKING 18F-LABELED PRECURSORS AND PEPTIDES, LABELED C-MET BINDING PEPTIDES, AND METHODS OF USE THEREOF<br/>[FR] PROCÉDÉS DE PRODUCTION DE PRÉCURSEURS ET DE PEPTIDES MARQUÉS AU 18F, PEPTIDES MARQUÉS DE LIAISON À C-MET ET PROCÉDÉS POUR LEUR UTILISATION
  申请人：US HEALTH

  公开号：WO2018022603A1

  公开（公告）日：2018-02-01

  Described herein are novel methods for the synthesis of radiolabeling synthons such as [18F]fluoronicotinic acid-2,3,5,6-tetrafluorophenyl ester, and also methods of labeling a protein or peptide comprising a free amine group. A novel c-Met binding peptide, and imaging methods, are also described.

  本文描述了一种合成放射性标记合成物（如[18F]氟烟酸-2,3,5,6-四氟苯酯）的新方法，以及标记具有自由氨基团的蛋白质或肽的方法。还描述了一种新的c-Met结合肽和成像方法。
• ORGANIC ELECTROLUMINESCENCE ELEMENT AND ELECTRONIC DEVICE
  申请人：Idemitsu Kosan Co.,Ltd.

  公开号：EP4108661A1

  公开（公告）日：2022-12-28

  An organic electroluminescence device includes an anode, an emitting layer, and a cathode in this order. The emitting layer contains a delayed fluorescent compound M2 and a compound M3 having at least one deuterium atom, and the compound M3 is not a compound having a partial structure represented by a formula (1C) or (2C). S1(M2) of the compound M2 and S1(M3) of the compound M3 satisfy a relationship of a numerical formula (Numerical Formula 1). In the formulae (1C) and (2C), Y41 to Y48 are each independently a N atom, CR, or a C atom bonded to another atom or the like in the compound M3, where each R is independently a H atom or a substituent, at least one of Y41 to Y48 is a N atom, and at least one of Y41 to Y48 is a C atom bonded to another atom or the like in the compound M3. S1M3>S1M2

  一种有机电致发光装置依次包括阳极、发光层和阴极。发射层包含延迟荧光化合物 M2 和具有至少一个氘原子的化合物 M3，而化合物 M3 并非具有式（1C）或（2C）所代表的部分结构的化合物。化合物 M2 的 S1(M2)和化合物 M3 的 S1(M3)满足数值式（数值式 1）的关系。在式 (1C) 和 (2C) 中，Y41 至 Y48 在化合物 M3 中各自独立地为 N 原子、CR 或与另一个原子或类似原子键合的 C 原子，其中每个 R 独立地为 H 原子或取代基，Y41 至 Y48 中至少有一个为 N 原子，Y41 至 Y48 中至少有一个为与另一个原子或类似原子键合的 C 原子。S1M3>S1M2